Prometheus Laboratories

Prometheus Laboratories

Prometheus Laboratories operates as a specialty clinical laboratory based in San Diego, California, with an established focus on precision-guided care for inflammatory bowel disease and other gastrointestinal disorders. The firm discovers, develops, and commercializes testing services that support clinicians across the patient journey, including disease interception, stratification, therapy selection, and monitoring. The company's core offering includes PredictrPK, a precision-guided dosing platform that uses Bayesian forecasting to quantify patient drug clearance and forecast drug exposure over time. PredictrPK currently covers biologics such as infliximab, adalimumab, vedolizumab, and ustekinumab, along with their biosimilars. In December 2025, Prometheus launched IBD Precis, a test featuring colonic markers to transform UC and CD assessment (per the firm, December 2025). The laboratory performs its tests under CLIA certification and College of American Pathologists accreditation. Prometheus performs more than 1 million tests annually, and its laboratory is CLIA-certified (05D0917432) and CAP-accredited (6805501). The firm's client services and billing support are based in San Diego. The company has not publicly disclosed its ownership structure, principals, or parent entity. Its website lists offices in San Diego and refers to international inquiries directed to a global email address, but does not detail additional locations. The firm's structural differentiator lies in its proprietary PredictrPK platform, which applies pharmacokinetic modeling to guide biologic dosing — a shift from standard therapeutic drug monitoring. Its tests are laboratory-developed and not FDA-cleared, positioning Prometheus within the regulated clinical laboratory space rather than as a traditional diagnostics or pharmaceutical company.